Keppra (levetiracetam) is not a benzodiazepine. It belongs to a completely different drug class called anticonvulsants, and it works through a mechanism that has nothing in common with how benzodiazepines function. The two drugs are sometimes used to treat the same conditions, particularly seizures, which is likely why they get confused. But they differ in nearly every important way: how they work in the brain, their side effect profiles, their potential for dependence, and their legal classification.
How Keppra Works in the Brain
Keppra’s mechanism is unusual even among seizure medications. It binds to a protein called SV2A, which sits on the surface of tiny sacs (synaptic vesicles) that neurons use to release chemical signals. By attaching to SV2A, Keppra modulates how these vesicles release their contents, essentially dialing down excessive nerve signaling that leads to seizures. Research published in the Proceedings of the National Academy of Sciences confirmed that SV2A is both necessary and sufficient for Keppra to bind, and that the drug is highly selective for this one protein. It doesn’t attach to the related proteins SV2B or SV2C.
This mechanism is entirely distinct from every other seizure medication on the market. Most anticonvulsants work by blocking sodium channels, enhancing inhibitory brain signaling, or reducing excitatory signaling. Keppra does none of these things in any direct way.
How Benzodiazepines Work Differently
Benzodiazepines like diazepam (Valium), lorazepam (Ativan), and clonazepam (Klonopin) work by enhancing the activity of GABA, the brain’s main calming chemical. They bind to a specific spot on the GABA receptor that’s physically separate from where GABA itself attaches. When a benzodiazepine occupies this spot, it shifts the receptor into a state that responds more strongly to GABA, making inhibitory signals in the brain more powerful. This is why benzodiazepines produce sedation, muscle relaxation, and anxiety relief in addition to seizure control.
Keppra has been specifically tested against benzodiazepine receptors and shows zero binding affinity for them. It also shows no affinity for GABA receptors, NMDA receptors, glycine receptors, or any of the other common receptor systems that most brain-active drugs target. The two medications operate through completely unrelated pathways.
Dependence and Controlled Substance Status
One of the most practically important differences between these drugs is their potential for dependence. Benzodiazepines are Schedule IV controlled substances in the United States because they carry a well-documented risk of physical dependence and withdrawal. People who take benzodiazepines regularly can develop tolerance, meaning they need higher doses for the same effect, and stopping abruptly can trigger dangerous withdrawal symptoms including rebound seizures.
Keppra carries no DEA scheduling whatsoever. It is not classified as a controlled substance. While its abuse and dependence potential hasn’t been formally studied in large human trials, the drug doesn’t interact with any of the receptor systems typically associated with addiction or withdrawal.
Side Effects Compared
Despite working differently, Keppra and benzodiazepines do share some surface-level side effects, which may be another reason people wonder if they’re related. Both can cause drowsiness and fatigue. Keppra can enhance the sedating effects of alcohol, cannabis, and opioids, much like benzodiazepines do.
Where Keppra stands apart is in its behavioral side effects. The most common complaints are neurobehavioral: mood swings, irritability, aggression, agitation, and in some cases depression or confusion. About 1% of patients experience more serious psychiatric effects like psychosis, hallucinations, or suicidal thoughts. Benzodiazepines, by contrast, tend to produce the opposite behavioral profile in most people, calming anxiety and reducing agitation (though paradoxical agitation can occur in some individuals).
Upper respiratory symptoms like sore throat and nasal congestion have been reported in 7% to 15% of people taking Keppra, a side effect that doesn’t have a parallel with benzodiazepines.
Drug Interactions and Metabolism
Keppra has an unusually clean pharmacokinetic profile. About 66% of each dose leaves the body unchanged through urine, and 24% gets converted to an inactive byproduct that’s also excreted in urine. It doesn’t rely on the liver’s cytochrome P450 enzyme system for metabolism, which means it rarely interferes with other medications. It also doesn’t bind significantly to proteins in the blood, further reducing interaction risk.
Most benzodiazepines, on the other hand, are processed through the liver’s P450 system and can interact with a wide range of other drugs. This makes Keppra a simpler choice for people already taking multiple medications, which is common in epilepsy treatment.
When Each Drug Is Used for Seizures
Both drugs treat seizures, but they fill very different roles. In a seizure emergency (status epilepticus), benzodiazepines are always the first drug given. Lorazepam or diazepam is administered intravenously to stop the seizure as quickly as possible. If the benzodiazepine fails, Keppra is one of the second-line options, alongside valproate and fosphenytoin.
For ongoing seizure prevention, the roles reverse. Benzodiazepines are rarely used as long-term maintenance medications because tolerance develops over weeks to months, gradually reducing their effectiveness. Keppra, by contrast, is one of the most widely prescribed daily seizure medications precisely because it maintains its effectiveness over time, has minimal drug interactions, and doesn’t carry dependence risk. It’s commonly prescribed for focal seizures, generalized tonic-clonic seizures, and myoclonic seizures in both adults and children.
So while you might encounter both drugs in the context of epilepsy treatment, they serve fundamentally different purposes: benzodiazepines for acute rescue, Keppra for daily prevention.